Aristo Bio-Tech and Lifescience Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDChemicals
The available domestic chemical proxies are mixed to weak. Fertilizers output was -8.0% YoY (2026-07) and sale quantity of fertilisers was 0.0% YoY (2026-05), although that high-frequency barometer is stale. FPI positioning is less negative than before, with net 3-month outflow only INR -11 crore versus INR -1229 crore in the prior 3 months to 2026-08-31, but the weak sector driver argues for a neutral stance.
PROS
- Company has delivered good profit growth of 32.2% CAGR over last 5 years
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.29x)
- Working capital cycle has improved - days down from 32 to 23
- Company generates healthy free cash flow
- Attractively priced for its growth - PEG of 0.2
CONS
- Equity base is being diluted - shares outstanding up 36.3%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| UPL | 573.85 | 23.98 | 48442.66 | 1.05 | -73.00 | 58.52 | 10181.00 | 10.47 | 12.00 | 13.43 |
| PIIND | 2257.50 | 29.40 | 34250.37 | 0.66 | 244.20 | -38.95 | 1702.30 | -10.43 | 16.00 | 21.69 |
| SUMICHEM | 477.00 | 41.09 | 23809.25 | 0.27 | 214.51 | 20.45 | 1063.35 | 0.62 | 23.39 | 21.94 |
| BAYERCROP | 3980.00 | 322.82 | 17886.95 | 3.77 | 321.60 | 15.39 | 1835.00 | -4.16 | 30.08 | 20.03 |
| SHARDACROP | 766.05 | 11.04 | 6911.34 | 1.96 | 88.02 | -38.36 | 1073.77 | 9.03 | 31.10 | 17.32 |
| DHANUKA | 980.30 | 14.72 | 4370.01 | 0.20 | 75.50 | 27.94 | 442.02 | 20.01 | 24.44 | 24.83 |
| RALLIS | 202.00 | 23.92 | 3928.27 | 1.49 | -14.15 | -274.26 | 507.54 | 7.70 | 13.23 | -0.56 |
| NACLIND | 157.65 | 298.53 | 3692.85 | 0.00 | 20.84 | 59.82 | 383.33 | -14.50 | 6.20 | 10.80 |
| BHAGCHEM | 257.45 | 121.29 | 3338.33 | 0.06 | 133.29 | 3249.84 | 1950.19 | 1475.55 | 4.55 | 15.65 |
| GSPCROP | 471.50 | 22.41 | 2193.36 | 0.21 | 263.94 | 1111.46 | 3859.95 | 1153.27 | 18.46 | 11.02 |
| BHARATRAS | 1157.60 | 13.43 | 1924.06 | 0.04 | 372.30 | 838.73 | 3381.60 | 796.03 | 16.63 | 15.19 |
| ARISTO | 108.00 | 10.24 | 73.52 | 0.56 | — | — | — | — | 12.96 | — |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
No standalone quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 202 | 201 | 167 | 166 | 218 | 245 | 318 | |
| 195 | 197 | 163 | 161 | 209 | 237 | 309 | |
| Operating Profit | 7 | 5 | 4 | 5 | 9 | 8 | 9 |
| OPM % | 3.38% | 2.24% | 2.60% | 3.12% | 3.99% | 3.44% | 2.92% |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Interest | 2 | 3 | 2 | 2 | 3 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
| Profit before Tax | 4 | 1 | 1 | 2 | 5 | 5 | 5 |
| Tax % | 31.06% | 27.84% | 28.20% | 27.60% | 24.83% | 27.96% | 25.68% |
| Net Profit | 3 | 1 | 1 | 1 | 4 | 4 | 4 |
| EPS | 5.66 | 2.02 | 2.15 | 2.87 | 6.72 | 5.72 | 5.97 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 4.78% | 6.99% | 8.38% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 10%
- 3 Years:
- 24%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 32%
- 3 Years:
- 42%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 8%
- 1 Year:
- -17%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 12%
- 3 Years:
- 13%
- Last Year:
- 11%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 7 | 7 | 7 |
| 6 | 7 | 8 | 10 | 23 | 27 | 31 | |
| 13 | 18 | 21 | 24 | 20 | 18 | 18 | |
| Trade Payables | 63 | 38 | 38 | 35 | 45 | 69 | 78 |
| 3 | 19 | 8 | 3 | 4 | 6 | 7 | |
| Total Liabilities | 91 | 88 | 81 | 77 | 100 | 127 | 141 |
| 8 | 8 | 12 | 14 | 16 | 22 | 24 | |
| Capital Work in Progress | 1 | 3 | 0 | 0 | 1 | 0 | 0 |
| 33 | 24 | 32 | 24 | 31 | 40 | 47 | |
| 0 | 0 | 0 | 0 | 0 | 57 | 56 | |
| Cash & Bank | 0 | 1 | 0 | 0 | 2 | 1 | 1 |
| 48 | 52 | 37 | 38 | 50 | 7 | 12 | |
| Total Assets | 91 | 88 | 81 | 77 | 100 | 127 | 141 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 9 | 2 | 3 | 7 | -2 | 8 | 10 | |
| Cash from Investing | -2 | -2 | -2 | -3 | -4 | -7 | -5 |
| Cash from Financing | -6 | 1 | -1 | -3 | 8 | -2 | -4 |
| -0 | 0 | -0 | 0 | 1 | -1 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for ARISTO
Loading news…
AI Stock Analyst
Aristo Bio-Tech and Lifescience Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account